Kornimate/medical-research-clean huggingface dataset:
hypertensive heart disease in dr congo

Conditions: Hypertensive Heart Disease

Summary: in this cross-sectional study, we will analyzed data from a tertiary referral congolese hospital to find whether or not congolese patients with hypertensive heart disease have multiple comorbid conditions. will report on the management and outcomes of the patients.

this will be done by collecting individual data on bmi, dyslipidemia, stroke, diabetes, serum creatinine, hdl, ldl, and urea levels for patients diagnosed with hypertensive heart disease.

Eligibility criteria:
inclusion criteria: * patients is 18 year or older * patient is diagnosed with hypertensive heart disease exclusion criteria: * patient is not 18 year or older * patient is not diagnosed with hypertensive heart disease

Keywords: comorbidities democratic republic of congo hypertensive heart disease management
improving adherence and commitment to treatment in diabetic patients

Conditions: Type 2 Diabetes

Summary: in the impact project, the investigators want to improve adherence and commitment to treatment.

in this study the investigators use 3 interventions in diabetic patients and one control, to find what is the best intervention to improve adherence to healthy life style and medication therapy. the 3 intervention as followed: 1) meetings and follow-up by the medical team; 2) meetings and follow-up by trained peers; 3) system for sending sms, operate according to algorithm.

Eligibility criteria:
inclusion criteria: 1. type 2 diabetes 2. age 30-70 3. oral medication or insulin 4. according to the hba1c test result, 0.5% above the target for the patient's personal balance and below the 10%, the most recent, but in any event not more than six months prior to the study patient recruitment 5. bmi\<35 6. patients speak and read hebrew 7. owners of a mobile phone that can receive text messages (sms messages/ notifications) and have the ability to use the application (relevant for the sms notification arm) exclusion criteria: 1. active malignant disease 2. creatinine levels above 2 3. getting medicines that elevate sugar levels as steroids, chemotherapy 4. three months after myocardial infraction (myocardial ischemia), surgical intervention, cardiac event 5. patients who are planning major surgery 6. patients who are planning a residential zone change 7. patients with acute complications of diabetes under active treatment (such as limb amputation) 8. patients diagnosed with unbalanced mental disorders 9. patients who can not sign the form on their own "informed consent" 10. patients suffering from dementia 11. patients who are not mobile (dependent on the therapist)

Keywords: imbalanced diabetic patients hba1c peers
kinesiotaping for normalizing scapular dyskinesis

Conditions: Scapular Dyskinesis

Summary: the 3-dimensional position and orientation of the scapula as well as muscle activation of upper trapezius (ut), lower trapezius (lt) and serratus anterior (sa) of asymptomatic dyskinetic sportspeole will be recorded during shoulder flexion and shoulder abduction, in loaded and unloaded conditions. participants will be assessed in standard condition and with two differents kinesiotaping techniques.

about 20 dyskinetic asymptomatic people will be involved in the study. the objective will be to compare two different kinesiotaping techniques in normalizing scapular kinematics. tridimensional-movement of the scapula and emg activity of periscapular muscles will be evaluated doing flexion (sagittal plane) and abduction (frontal plane) movements. emg acquisitions : the electromyographic (emg) signals are collected with trigno standard and trigno mini wireless sensors (delsys, boston, ma, usa) using silver-contact bipolar bar electrodes with ﬁxed 10 mm inter-electrode spacing \[49\]. three of the main scapular stabilizing muscles of the shoulder are investigated: upper trapezius, lower trapezius and serratus anterior. electrodes are placed on the dyskinetic side. in case of bilateral scapular dyskinesis, electrodes are placed on the side where the most important dysfunction was observed. data are acquired at a sample frequency of 1000 hz. tridimensionnal assessment: scapular kinematics is assessed using a three-dimensional motion analysis system, an optoelectronic system based on active markers (codamotion, charnwood dynamic, uk). for that purpose, four codamotion cx1 units are used, at a sampling of 100 hz. fifteen active markers were placed on the skin of the subject on the same side as emg electrodes: 4 on the thorax, 6 on the scapula, 4 on the arm and 1 on the acromio-clavicular joint. procedure : * warm up : 2x10 shoulder internal and external rotations * maximum voluntary isometric contraction (mvic) * 10 mouvements of abduction (frontal plane) + 10 mouvements of flexion (sagittal plane), with and without load in each condition (without kinesiotaping, with a first kinesiotaping technique and with a second kinesiotaping technique). the order of the different conditions will be randomised.

Eligibility criteria:
inclusion criteria: * unilateral or bilateral scapular dyskinesis (visual evaluation, "yes-no method") * scapular downward rotation at rest exclusion criteria: * asymmetry of length of lower limbs * scoliosis or dorsal hyperkyphosis shoulder surgical history * shoulder pain, shoulder injury (muscular, osseous, ligamentary, tendinous) or positive tendinous and impingement tests (jobe, patte 0°, patte 90°, lift off test, palm-up test).
the effects of cold water immersion with different dosages (duration and temperature variations) on heart rate variability post-exercise recovery

Conditions: Cryotherapy Effect

Summary: the aim of the present study was to investigate the effects of cold water immersion (cwi) during post-exercise recovery with different durations and temperatures on heart rate variability (hrv) indices. 100 participants performed a protocol of jumps and a wingate test, and immediately afterwards were immersed in cold water, according to the characteristics of each group (cg: control; g1: 5' at 9±1°c; g2: 5' at 14±1°c; g3: 15' at 9±1°c; g4: 15' at 14±1°c). analyses were performed at baseline, during the recuperative technique (trec) by cwi and 20, 30, 40, 50 and 60 minutes post-exercise. the hrv indices average of all rr intervals in each analysis period (mean rr), standard deviation of normal r-r intervals (sdnn), square root of the mean of the sum of the squares of differences between adjacent r-r intervals (rmssd), spectral components of very low frequency (vlf), low frequency (lf) and high frequency (hf), scatter of points perpendicular to the line of identity of the poincaré plot (sd1) and scatter points along the line of identity (sd2) were assessed. comparisons between groups and moments were performed using the technique of analysis of variance for repeated measures in two scheme factors. a significance level of p\<0.05 was considered.


Eligibility criteria:
inclusion criteria: * male sex * healthy * aged between 18 and 30 years * classified as physically active through the international physical activity questionnaire exclusion criteria: * smokers * alcoholics * use drugs that influenced cardiac autonomic activity * cardiovascular, metabolic or endocrine diseases.

Keywords: recovery of function autonomic nervous system heart rate variability cryotherapy immersion
neonatal erythropoietin and therapeutic hypothermia outcomes in newborn brain injury (neato)

Conditions: Hypoxic-ischemic Encephalopathy; Neonatal Encephalopathy; Birth Asphyxia

Summary: hypoxic-ischemic encephalopathy (hie), a condition of reduced blood and oxygen flow to a baby's brain near the time of birth, may cause death or neurologic disability. cooling therapy (hypothermia) provides some protection, but about half of affected infants still have a poor outcome. this clinical trial will determine if the drug erythropoietin, given with hypothermia, is safe to use as a treatment that may further reduce the risk of neurologic deficits after hie.

this phase i/ii clinical trial is designed to demonstrate: 1. the feasibility of recruiting, enrolling and following 50 patients with moderate to severe hie at 5 sites, while meeting specified recruitment and follow-up target goals. 2. the safety of high-dose epo therapy in neonates with hie with respect to systemic organ function and general growth parameters. 3. the value of brain mri/mrs performed at 4-7 days of age as a biomarker of motor function at 12 months of age.

Eligibility criteria:
inclusion criteria: * newborns ≥ 36 weeks gestation, \< 23 hours of age at time of consent, must meet all 3 inclusion criteria to be eligible for the study: 1. perinatal depression = at least one of the following: a) apgar ≤5 at 10 min or b) required resuscitation (endotracheal or mask ventilation, or chest compressions) at 10 min or c) ph \< 7.0 or base deficit ≥15 in cord, arterial, or venous blood obtained at \<60 min of age; 2. moderate to severe encephalopathy = at least 3 of 6 modified sarnat criteria present between 1-6 h of birth: a) reduced level of consciousness; b) decreased spontaneous activity; c) hypotonia; d) decreased suck; e) decreased moro reflex; or f) respiratory distress including periodic breathing or apnea; and 3. hypothermia = passive or active cooling begun by 6 hours of age. exclusion criteria: * intrauterine growth restriction (bw \<1800 g); * major congenital malformation; suspected genetic syndrome, metabolic disorder or torch infection; * head circumference \< 2 sd for gestation; * infant for whom withdrawal of supportive care is being considered; or * anticipated inability to collect primary endpoint at 12 months of age.

Keywords: erythropoietin therapeutic hypothermia
a new treatment protocol for paediatric mandibular condylar fractures

Conditions: Fractures

Summary: this study aim to evaluate the clinical and radiographic outcomes of mandibular condylar fractures in pediatrics treated simply with a mandibular manipulation technique accompanied by mouth opening training.

there is a consensus on nonsurgical approach is a priority for paediatric condylar fractures, but a recognized nonsurgical method for treating children with condylar fractures is still a highly debated theme. the purpose of this study is to investigate the effect of a new nonsurgical method simply using a mandibular manipulation technique and mouth opening training in managing children with condylar fractures. spiral computed tomography (ct) or cone beam computed tomography (cbct) will be taken before treatment when the patients present to the department. condylar fracture classification is defined according to spiessl \& schroll. these patients are then treated termly with a mandibular manipulation technique reported by farrar, which is an effective treatment method to reset the physiological positional relationship between condyle and disc. neither intermaxillary fixation nor guiding elastics will be used after hand manipulation. then patients are told to persist in mouth opening training at home everyday. the mouth opening training is performed as follow: patients are told to try to close his mouth in intercuspal position at first, then open their mouth as wide as possible(the reference maximal mouth opening is as wide as the mouth opening after treatment in last time), then closed back to the intercuspal position again. patients are recommended to follow up at every week at first two months, then every 2 weeks at third months, 6th months, 1 year after first treatment, then yearly afterward. the mandibular manipulation is performed at every follow-up. meanwhile, the maximal mouth opening (mmo) is recorded before and after hand manipulation treatment. so do the occlusion status, deviation during opening, as well as subjective symptoms of temporomandibular joints. at first moth, 3rd month, 6th month, 1 year, then every year after first treatment, cbct is performed.

Eligibility criteria:
inclusion criteria: * suffer mandibular condylar fracture * voluntary patient * with no concomitant displaced jaw fractures * the fracture-treatment interval time is less than 2 months exclusion criteria: * life-threatening patient * patient can not do the guide line

Keywords: children mandible condylar fracture conservative treatment functional treatment
ebd rct trial in living donor liver transplantation

Conditions: Liver Transplantation; Liver Transplant; Complications; Bile Stricture; Bile Leakage From Biliary Anastomosis

Summary: this study was designed to demonstrate incidence of biliary complication rates after living donor liver transplantation according to the implantation of external biliary drainage throug duct-to-duct anastomosis site.

biliary complication is the most common complications after liver transplantation, and it happens more often after living donor liver transplantation (ldlt) than deceased donor liver transplantation. many transplant centers adopted their own methods to improve biliary complications after ldlt. one suggested method is the application of external biliary drainage (ebd). a prospective study was planned to demonstrate effect of ebd on biliary complication after ldlt. patients who underwent ldlt with duct-to-duct anastomosis will be randomly assinged to application of ebd or conventional duct-to-duct anastomosis without ebd according to a computer generated randomization sequence and allocated in a 1:1 ratio to one of two groups. primary outcome is biliary complication incidence 1 year after ldlt.

Eligibility criteria:
inclusion criteria: * living donor liver transplantation * adult patient (\>=18 years old) * patients who are available for at least 3 year follow-up after ldlt exclusion criteria: * patients requring hepaticojejunostomy due to anatomical factor or underlying disease * re-transplantation * multiorgan transplantation * emergency transplantation
effect of photobiomodulation therapy in patients with hashimoto's thyroiditis

Conditions: Hashimoto Thyroiditis; Thyroiditis

Summary: the standard lifelong treatment for hashimoto's thyroiditis (ht), a chronic autoimmune disease, is levothyroxine (lt4) therapy. despite lt4 replacement therapy, patients continue to experience persistent fatigue, deterioration in psychological and general well-being. our study was conducted to investigate the effects of photobiomodulation therapy (pmbt) combined with lt4 replacement therapy on fatigue and behavioural status in patients with ht.

photobiomodulation therapy (pmbt) induces a wide range of molecular, cellular and tissue-based therapeutic effects through a biostimulation process by inducing a photochemical reaction in the cell. some investigations show useful effects of this treatment with regard to thyroid function, autoimmunity and vascularisation in patients with hashimoto's thyroiditis (ht). however, little is known about the efficacy of pmbt on neuromuscular symptoms and behavioural status. therefore, in this study we aim to contribute the present literature on pmbt and to determine the clinical efficacy of pmbt. to the best of our knowledge, this study is the first paper to discuss the symptomatic efficacy of pmbt in patients with ht. here, we investigate the effects of pmbt applied in combination with lt4 treatment on fatigue, sleep quality and behavioural status in people diagnosed with ht.

Eligibility criteria:
inclusion criteria: * the study included patients over the age of eighteen years who were diagnosed with ht by a specialist physician and followed up with lt4 treatment. exclusion criteria: * exclusion criteria were acute infection, use of immunosuppressants, immunostimulants and drugs that interfere with the production, transport and metabolism of thyroid hormones (e.g. corticosteroids, lithium and amiodarone), thyroid nodules, tracheal stenosis, history of serious illness (e.g. cancer, ischaemic coronary artery disease, stroke, renal and liver failure), history of exposure to ionising radiation or neoplasia in the cervical region, malignancy and thyroid surgery; cancer, ischaemic coronary artery disease, stroke, renal and hepatic failure), history of exposure to ionising radiation or neoplasia in the cervical region, history of malignancy and thyroid surgery, hypothyroidism caused by postpartum thyroiditis, pregnancy and lactation, neurological and psychiatric disorders.

Keywords: anxiety depression fatigue photobiomodulation therapy low level laser therapy
kyleena satisfaction study / observational study on user satisfaction with the levonorgestrel intrauterine delivery system kyleena (lng-ius 12) in new contraceptive users and after switching from another contraceptive method

Conditions: Contraception

Summary: the main goal of this non-interventional study (nis) is to evaluate user satisfaction with kyleena in a real-life setting and to identify factors which influence user satisfaction, taking into account previously used contraceptive methods and reasons for use of kyleena.


Eligibility criteria:
inclusion criteria: * women requesting contraception with kyleena. the woman's informed decision for contraception with kyleena was made before and independently from the study as per investigator's routine practice * written informed consent. exclusion criteria: * contraindications for kyleena according to the local market authorization/smpc * mental incapacity to consent and provide data during the observational study * women participating in an investigational program with interventions outside of routine clinical practice.

Keywords: long-acting contraception, unintended pregnancy satisfaction bleeding profile amenorrhea
study to evaluate efficacy, safety, and tolerability of imu-838 in patients with progressive multiple sclerosis

Conditions: Multiple Sclerosis

Summary: multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy, safety, and tolerability of imu-838 in patients with progressive multiple sclerosis - calliper

this study will be a multicenter, randomized, double-blind, placebo-controlled study with a blinded main treatment period (mt) and an open label period (ole) to evaluate the efficacy, safety, and tolerability of imu838 in adult patients with pms. the study will consist of the following periods: screening period: approximately 28 days main treatment period: up to 120 weeks (approximately 2 years) open label extension period: up to approximately 8 years

Eligibility criteria:
inclusion criteria: * adult patients, age 18 to 65 years (inclusive). * edss score at screening between 3.0 to 6.5 (both inclusive) * no evidence of relapse in the last 24 months before randomization, and patients diagnosed according to 2017 revised mcdonald criteria 1 and the 2013 revised classification of disease courses 2 as either 1. spms inpatients showing evidence of gd+mri lesions (active spms) or without gd+mri lesions (non-active spms) in the last 12 months, or 2. ppms * willingness and ability to comply with the protocol. * written informed consent given by the patient before the beginning of any study-related procedure. * documented evidence of disability progression not temporarily related to a relapse in the last 24 months before randomization, adjudicated by a central independent reviewer exclusion criteria: * any disease other than ms that may better explain the signs and symptoms, including a history of complete transverse myelitis. * clinical signs or presence of laboratory findings suggestive for neuromyelitis optica (nmo) spectrum disorders or myelin oligodendrocyte glycoprotein (mog)-associated encephalomyelitis (i.e.,presence of anti-nmo \[aquaporin-4\] antibodies or anti-mog antibodies). * previous or current use of ms treatments lifelong, or within a pre-specified time period. * use of any investigational product within 8 weeks or 5 the respective pk half- life before the date of informed consent, whichever is longer, and throughout the study.for some investigational products, prolonged biological effects beyond 8 weeks should be considered. * positive test for severe acute respiratory syndrome coronavirus 2 (sars- cov-2) within14 days before randomization. in case of known sars-cov-2 infection, patients should be randomized no earlier than 14 days after 2 consecutive negative tests confirming virus negative status.the screening period can be extended for these patients to accommodate the required virus negativity. * positive ifn-gamma release assay (igra) for mycobacterium tuberculosis at sv1. * positive hepatitis b virus (hbv) surface antigen, hepatitis b core antibody, positive hepatitis c virus (hcv) antibody, and/or hiv-antigen-antibody test at sv1.

Keywords: progressive multiple sclerosis
evaluation of tooth sensitivity and whitening effects of different content teeth whitening agents

Conditions: Healthy Volunteers; Discoloration of Teeth; Bleaching Sensitivity

Summary: the goal of this clinical study is to evaluate the success of different whitening agents in whitening teeth in healthy volunteers aged 18-50. also, patients' tooth sensitivity will be assessed after application. the main questions it aims to answer are: is the teeth whitening success of different whitening agents similar? did participants develop tooth sensitivity to whitening agents? the researchers will compare the whitening success of 3 different whitening agents and changes in tooth sensitivity within 1 year after application. participants: whitening agent will be applied in the clinic visit our clinic for checkups and records after 1 week, 2 weeks, 1 month, 2 months, 4 months , 6 months and 1 year after application

the participants in the study were healthy volunteers between the ages of 18-50. the number of volunteers was determined by using other studies similar to this study. there are 60 volunteers in three groups, 20 volunteers in each group. a different whitening agent is applied to each group by the researcher. the researcher did not include volunteers with poor oral hygiene, smoking, tooth sensitivity, caries, or medication use in the study. the researcher began the study by performing color measurement and sensitivity assessment before the procedure. then he applied the whitening agent. the volunteers who underwent the whitening procedure will be evaluated in terms of both color measurements and sensitivity changes at the end of the treatment, 1st week, 2nd week, 1st month, 2nd month, 4th month, 6th month, and 1st year control sessions. each patient has their own evaluation form. there are different fields for both color and sensitivity in the form according to the control dates. all numerical data are recorded in their own fields.

Eligibility criteria:
inclusion criteria: * vital teeth * healthy gums * no tooth sensitivity * external discoloration ( tea,coffee..) * good oral hygiene * no allergy to the material to be used exclusion criteria: * decayed and devital teeth * presence of gingival bleeding * history of trauma * presence of fractures, cracks and aesthetic restoration * smoking

Keywords: bleaching agents bleaching agent \( boost 40%\) bleaching teeth discoloration of teeth sensitivity, tooth